BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 29409060)

  • 1. Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism.
    Tevosian SG; Ghayee HK
    J Clin Endocrinol Metab; 2018 May; 103(5):1779-1789. PubMed ID: 29409060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma.
    Rao JU; Engelke UF; Rodenburg RJ; Wevers RA; Pacak K; Eisenhofer G; Qin N; Kusters B; Goudswaard AG; Lenders JW; Hermus AR; Mensenkamp AR; Kunst HP; Sweep FC; Timmers HJ
    Clin Cancer Res; 2013 Jul; 19(14):3787-95. PubMed ID: 23723300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pheochromocytomas and paragangliomas in humans and dogs.
    Galac S; Korpershoek E
    Vet Comp Oncol; 2017 Dec; 15(4):1158-1170. PubMed ID: 28120550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas.
    Guo D; Zhao X; Wang A; Xie Q; Xu X; Sun J
    Hum Pathol; 2019 Apr; 86():155-162. PubMed ID: 30594747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings.
    Aygun N; Uludag M
    Sisli Etfal Hastan Tip Bul; 2020; 54(2):159-168. PubMed ID: 32617052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Warburg effect's manifestation in aggressive pheochromocytomas and paragangliomas: insights from a mouse cell model applied to human tumor tissue.
    Fliedner SM; Kaludercic N; Jiang XS; Hansikova H; Hajkova Z; Sladkova J; Limpuangthip A; Backlund PS; Wesley R; Martiniova L; Jochmanova I; Lendvai NK; Breza J; Yergey AL; Paolocci N; Tischler AS; Zeman J; Porter FD; Lehnert H; Pacak K
    PLoS One; 2012; 7(7):e40949. PubMed ID: 22859959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.
    Rai SK; Bril F; Hatch HM; Xu Y; Shelton L; Kalavalapalli S; Click A; Lee D; Beecher C; Kirby A; Kong K; Trevino J; Jha A; Jatav S; Kriti K; Luthra S; Garrett TJ; Guingab-Cagmat J; Plant D; Bose P; Cusi K; Hromas RA; Tischler AS; Powers JF; Gupta P; Bibb J; Beuschlein F; Robledo M; Calsina B; Timmers H; Taieb D; Kroiss M; Richter S; Langton K; Eisenhofer G; Bergeron R; Pacak K; Tevosian SG; Ghayee HK
    Metabolism; 2020 Sep; 110():154297. PubMed ID: 32562798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.
    Crona J; Delgado Verdugo A; Maharjan R; Stålberg P; Granberg D; Hellman P; Björklund P
    J Clin Endocrinol Metab; 2013 Jul; 98(7):E1266-71. PubMed ID: 23640968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical outcome of laparoscopic surgery, including laparoendoscopic single-site surgery, for retroperitoneal paraganglioma compared with adrenal pheochromocytoma.
    Hattori S; Miyajima A; Hirasawa Y; Kikuchi E; Kurihara I; Miyashita K; Shibata H; Nakagawa K; Oya M
    J Endourol; 2014 Jun; 28(6):686-92. PubMed ID: 24499341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PHOX2B is a Sensitive and Specific Marker for the Histopathological Diagnosis of Pheochromocytoma and Paraganglioma.
    Miyauchi M; Akashi T; Furukawa A; Uchida K; Tamura T; Ando N; Kirimura S; Shintaku H; Yamamoto K; Ito T; Miura K; Kayamori K; Ariizumi Y; Asakage T; Kudo A; Tanabe M; Fujii Y; Ishibashi H; Okubo K; Murakami M; Yamada T; Takemoto A; Bae Y; Eishi Y; Ohashi K
    Endocr Pathol; 2022 Dec; 33(4):506-518. PubMed ID: 36029394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options.
    Eid M; Foukal J; Sochorová D; Tuček Š; Starý K; Kala Z; Mayer J; Němeček R; Trna J; Kunovský L
    Cancer Med; 2023 Jul; 12(13):13942-13957. PubMed ID: 37145019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.
    Jochmanová I; Yang C; Zhuang Z; Pacak K
    J Natl Cancer Inst; 2013 Sep; 105(17):1270-83. PubMed ID: 23940289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and paragangliomas.
    Oudijk L; van Nederveen F; Badoual C; Tissier F; Tischler AS; Smid M; Gaal J; Lepoutre-Lussey C; Gimenez-Roqueplo AP; Dinjens WN; Korpershoek E; de Krijger R; Favier J
    PLoS One; 2015; 10(3):e0121361. PubMed ID: 25794004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
    Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
    Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Stem Cells in Pheochromocytoma and Paraganglioma.
    Scriba LD; Bornstein SR; Santambrogio A; Mueller G; Huebner A; Hauer J; Schedl A; Wielockx B; Eisenhofer G; Andoniadou CL; Steenblock C
    Front Endocrinol (Lausanne); 2020; 11():79. PubMed ID: 32158431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
    Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
    Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
    Fishbein L; Khare S; Wubbenhorst B; DeSloover D; D'Andrea K; Merrill S; Cho NW; Greenberg RA; Else T; Montone K; LiVolsi V; Fraker D; Daber R; Cohen DL; Nathanson KL
    Nat Commun; 2015 Jan; 6():6140. PubMed ID: 25608029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-specific differences in the tumor metabolite profile of pheochromocytoma and paraganglioma using untargeted and targeted metabolomics.
    Rao JU; Engelke UF; Sweep FC; Pacak K; Kusters B; Goudswaard AG; Hermus AR; Mensenkamp AR; Eisenhofer G; Qin N; Richter S; Kunst HP; Timmers HJ; Wevers RA
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E214-22. PubMed ID: 25459911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas.
    Amorim-Pires D; Peixoto J; Lima J
    Cytogenet Genome Res; 2016; 150(3-4):227-241. PubMed ID: 28231563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma.
    Puar T; van Berkel A; Gotthardt M; Havekes B; Hermus AR; Lenders JW; van Marken Lichtenbelt WD; Xu Y; Brans B; Timmers HJ
    J Clin Endocrinol Metab; 2016 Jan; 101(1):224-32. PubMed ID: 26574955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.